Placebo-Matching Atogepant

Phase 3

AbbVie

Placebo-Matching Atogepant is one of 4 therapeutic programs targeting Episodic Migraine. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Episodic MigraineRecruiting

Episodic MigrainePhase 3

Recruiting

Competition

Competitive Landscape

6 competitors in Episodic Migraine

#DrugCompanyPhaseTrials

XEOMIN

MMerz Pharmaceuticals GmbH

Phase 3

1 2

Qulipta

AbbVie

Phase 3

1 3

IPN10200

Ipsen

Phase 2

1 4

Placebo-Matching Atogepant

AbbVie

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Episodic Migraine

NCT05711394

Clinical

Trials by Indication[1]

Episodic Migraine1 trial

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 Years of Age.

Recruiting· AbbVie logo

AbbVie·Phase 3·NCT05711394·450 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Placebo-Matching Atogepant. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Placebo-Matching Atogepant. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: AbbVie

Placebo-Matching Atogepant

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Episodic Migraine1 trial

References

Drug Info

Quick Facts

Related News